Research workbench
Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor npd-356
Analyse Crystal structure of human phosphodiesterase 4D2 catalytic domain with… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.
- PDB
- 6FE7
- Type
- protein
- Length
- 1,301 residues
- Chains
- 4
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Camp-specific 3',5'-cyclic phosphodiesterase 4D
- EC
- 3.1.4.53
- UniProt
- Q08499
- Ligands
- D62, ZN, MG
- Pockets
- 16 · best druggability 0.80
Structure
x-ray diffraction · 3 distinct chains · 66% helix, 1% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Camp-specific 3',5'-cyclic phosphodiesterase 4D (EC 3.1.4.53) | protein | 330 | 66% helix, 1% strand | Q08499 |
| B | Camp-specific 3',5'-cyclic phosphodiesterase 4D (EC 3.1.4.53) | protein | 323 | 66% helix, 1% strand | Q08499 |
| C, D | Camp-specific 3',5'-cyclic phosphodiesterase 4D (EC 3.1.4.53) | protein | 324 | 66% helix, 1% strand | Q08499 |
Ligands and binding sites
- D62 · (4as,8ar)-2-(1-{2-aminothieno[2,3-d]pyrimidin-4-yl}piperidin-4-yl)-4-(3,4- dimethoxyphenyl)-1,2,4A,5, 8,8A-hexahydrophthalazin-1-one · ligand · 4 copies · chains A, B, C, D
- ZN · Zinc ion · metal · 4 copies · chains A, B, C, D
- MG · Magnesium ion · metal · 4 copies · chains A, B, C, D
- EDO · 1,2-ethanediol · additive · 58 copies · chains A, D, C, B
- PEG · Di(hydroxyethyl)ether · additive · 14 copies · chains A, C, B, D
- EPE · 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid · additive · 5 copies · chains A, B, C, D
- PG4 · Tetraethylene glycol · additive · 2 copies · chains A, C, D
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
16 pockets found on a 1 Å grid, 10 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 389 | 0.80 | 0.89 | 60 | EDO |
| 2 | 329 | 0.80 | 0.90 | 51 | EDO |
| 3 | 298 | 0.76 | 0.89 | 40 | PEG, EDO, PG4 |
| 4 | 414 | 0.72 | 0.83 | 39 | MG, EDO, D62 |
| 5 | 388 | 0.72 | 0.83 | 38 | MG, EDO, D62 |
Interfaces
6 interfaces between chains.
- B–D · 921 Ų buried · 19 hydrogen bonds · protein-protein
- A–C · 911 Ų buried · 15 hydrogen bonds · protein-protein
- A–B · 697 Ų buried · 14 hydrogen bonds · protein-protein
- C–D · 653 Ų buried · 12 hydrogen bonds · protein-protein
- A–D · 237 Ų buried · 8 hydrogen bonds · protein-protein
Compared structures
- 6FE7 · Crystal structure of human phosphodiesterase 4D2 catalytic domain with inhibitor NPD-356 · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt Q08499
- Elsewhere: RCSB PDB 6FE7 · PDBe 6FE7 · UniProt Q08499
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.